A blinded retrospective study was conducted to investigate remission and recurrence of lymphoma in dogs receiving chemotherapy. The objective was to compare clinicians' assessment using palpation and cytology to the results of serum biochemical tests for haptoglobin (Hapt) and C-reactive protein (C-RP). These biochemical test results were combined using a diagnostic algorithm developed using data from 344 individual dogs. This multivariate approach, termed the canine lymphoma blood test (cLBT), was used to follow 57 dogs during and after treatment. cLBT of remission and recurrence compared well with clinicians' assessment and differentiated dogs in remission and those with recurring disease before appearance of lymphadenopathy (P < 0.001). The cLBT demonstrated prognostic potential based on pre-treatment values on dogs with shorter survival times and on those achieving the lowest cLBT score during treatment that showed longer survival times. The test, therefore, demonstrates potential to assist in monitoring treatment of canine lymphoma.
Introduction
Lymphoma is one of the most common malignancies to affect dogs. 1 -5 The disease is responsible for approximately 5% of all malignant canine cancers with an estimated annual incidence of approximately 25 per 100,000 dogs. 6, 7 The malignancy results from mutations in lymphoreticular cells and is generally seen in lymphoid tissues such as the lymph nodes and spleen, but it can affect any tissue in the body. The disease usually presents as painless swellings in the peripheral lymph nodes, 8 however, diagnosis is often complicated by lymphoid proliferation in internal organs such as the alimentary tract, mediastinum and bone marrow.
Definitive diagnosis requires cytological examination of tissue from fine needle aspirate (FNA), or, preferably histological classification of a biopsy collected from the affected tissue. T-cell lymphoma generally exhibits poorer prognosis and shows greater chemoresistance than B-cell lymphoma. Consequently, immunophenotyping is recommended to determine whether the malignancy is of B-or T-cell origin. 9, 10 Lymphoma is a complex disease, however, patients respond relatively well to chemotherapy. 11 It is routinely classified as low, intermediate or high grade. 12 The low-grade disease is characterized by cells with a low mitotic rate, slow development and low chemosensitivity. Patients exhibit relatively long survival times. Around 80% of lymphoma cases fall into the intermediate and high-grade categories. These malignancies are made up of cells with a high mitotic rate resulting in the disease developing rapidly. However, the disease invariably recurs and the second round treatment is considered to be less effective due to the development of resistance to the chemotherapy drugs, generally producing only short-lived results. 13 For this reason, close monitoring of dogs undergoing chemotherapy is important. The same is true for dogs that have entered remission and ceased treatment. 14 It is believed that re-induction or rescue therapy may be more effective when recurrence is detected in its early stages. 11 Re-induction therapy is recommended at the first recurrence, and this usually involves reintroducing the original induction protocol. However, the likelihood of response and duration of a second remission period are approximately half of that achieved by the initial protocol. After re-induction, some dogs will experience long-term remission, although there is currently no way of predetermining this response. When re-induction fails, rescue agents which were not included in the original protocol may be used. These include single agents such as lomustine, mitoxantrone or actinomycin D and also combination therapies such as MOPP (methclorethamine, vincristine, procarbazine and prednisolone). 15, 16 Response rates are reported to be in the range of 40-50%, but median survival times are only in the region of 2 months.
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Monitoring for disease remission/recurrence is usually performed by palpation of peripheral lymph nodes. 8 However, this can be a very subjective procedure which is only capable of detecting gross changes in peripheral lymph nodes. Biochemical methods which look for circulating biomarkers of the disease have the potential to provide greater objectivity whilst also detecting changes which precede peripheral lymphadenopathy. 17 In this context, serum thymidine kinase (a generic marker of cell proliferation) has been used for many years to monitor for disease recurrence in humans, 18, 19 but has never gained widespread application in veterinary medicine, 20 -22 most likely due to the poor specificity of existing tests. Indeed, Elliott et al. 21 have questioned the clinical utility of using thymidine kinase to monitor dogs during treatment for lymphoma.
Previous reports have shown that C-reactive protein (C-RP) and haptoglobin (Hapt), apart from their diagnostic usefulness in human nonHodgkin's lymphoma, could be included in the differential diagnosis of dogs with severe acute lymphatic neoplasias, such as high-grade lymphoma. 23 Similarly, evaluation of the C-RP levels in a canine population treated with cytotoxic drugs showed great potential in determining the remission status of dogs, 7 especially when combined with other clinical biomarkers.
In a personal communication with the authors, Professor Brian Mooney (Gehrke Centre of Proteomics, University of Missouri, Columbia) in 23 March 2012, investigated a canine sample set of 11 serum samples with SDS-PAGE, revealing a prominent band at approximately 35 kDa area. This band was differentially expressed in the samples and followed a clear trend of presence in the lymphoma samples (n = 5) and absence in lymphoma negative samples (n = 6), including non-healthy dogs. In-gel digestion with trypsin followed by HPLC coupled with mass spectrometry was used to confidently identify this protein as Hapt (data not shown). A total of 45% of the sequence was defined by identified peptides matching the beta portion of the translated Hapt and not the alpha portion .
The purpose of this study is to show that a novel approach of using multiple biomarkers, C-RP and Hapt along with age, sex and lymphadenopathy status combined with multivariate analysis can be used to monitor the remission status of canine lymphoma. Data are presented from a retrospective, blinded study of 57 dogs diagnosed with lymphoma prior to, during and after chemotherapy treatment with the aim of comparing the presence of clinical signs of lymphoma as determined by palpation and cytology to the results of the canine lymphoma blood test (cLBT).
Materials and methods

Serum samples and patients
Totally 196 sequential serum samples were collected over a 4-year period (2008-2012) from 57 dogs undergoing chemotherapy treatment for lymphoma visiting two veterinary referral practices (Veterinary Clinic Korte Akkeren, Gouda, Netherlands where at least 50% decrease was observed in the measurement of the affected lymph nodes (with no other nodes being involved); and progressive disease (PD) where, following treatment, a patient failed to attain the criteria needed for CR or PR and an increase of more than 50% in the size of the lymph nodes occurred. In this study disease recurrence was confirmed via cytology in all cases. Remission could not be confirmed using FNA, due to the difficulty of aspirating a normal lymph node and the diagnosis had to be based on clinician's assessment. All samples were residual blood volumes used with owner consent and with ethical approval, i.e. the dogs were bled for other routine tests and any surplus serum was used for this study. The follow-up sampling intervals for each patient were mostly based on the chemotherapy administration dates determined by the treating veterinarian. Consequently, blood samples were not taken at every visit of the dog to the clinic and therefore the samples represent different time points and different remission states dependent on the timing of each dog's visits to the veterinarian. The population comprised 33 female and 24 male, with an age range 
Diagnosis of lymphoma
Diagnosis of lymphoma and clinical staging were based on clinical presentation, physical examination and microscopic examination of FNA from enlarged lymph nodes as determined by the veterinarians supplying the serum samples. At Dick White Referrals, immunophenotype was determined on all samples using flow cytometry and cytology at Clinic Korte Akkeren. Clinical staging of the patients was performed according to the WHO staging system (Table 2) .
Chemotherapy treatment
The dogs were treated according to modified Wisconsin-Madison protocols (Tables 3 and 4 ). All relapsed cases were re-induced to the same protocol and those that did not respond were further induced to a rescue protocol (lomustine). Treatment dates, remission dates and time to progression dates along with cause of death were recorded.
Acute phase protein assays
All serum samples were separated and stored at −20 ∘ C on site and analysed batches. C-RP concentrations were measured using ELISA (SensiPak 
• 
• Canine CRP Elisa Kit, Avacta Animal Health, Wetherby, UK) and Hapt levels were measured using a biochemical test (SensiPak Canine Haptoglobin Biochemical Test Kit, Avacta Animal Health Wetherby, UK).
Development of multivariate algorithm
All the data obtained from the samples utilized in this study were processed by a multivariate algorithm designed by the University of Leicester School of Mathematics. 24 This algorithm was previously "taught" using a database comprising serum C-RP and Hapt values, plus age, sex and presence of lymphadenopathy plus disease confirmatory follow-up data from a separate group of 344 dogs, comprising those diagnosed with lymphoma (86), healthy dogs (73) and control animals diagnosed with diseases which present with symptoms similar to lymphoma (185), such as benign lymphadenopathy, hypercalcaemia, infection, inflammation, other malignancies, vomiting, diarrhoea, polyuria, polydipsia, lethargy, weight loss, thyroid disorders, pancreatitis and irritable bowel syndrome. Diagnosis of lymphoma in positive dogs in this group was confirmed either via FNA or histology. The non-lymphoma group comprised of dogs that showed no clinical evidence of the disease for a minimum period of 6 months after the original serum sample was taken. The algorithm uses three distinct analytical processes to weigh the probability of lymphoma in each new dog being presented to it. The algorithm combines decision trees, k nearest neighbour (kNN) analysis and probability density function estimation. 25 The decision tree employs three different impure-based criteria: information gain, Gini gain and DKM splitting criteria. 26 The kNN analytical component employed three versions of kNN methods: kNN with Euclidean distance, 27 kNN with Fisher's distance transformation and the advanced adaptive kNN. 28 In this original cohort of 344 dogs used to teach the algorithm, serum C-RP and Hapt values, plus age and sex of each dog were obtained at diagnosis prior to treatment and also at each visit to the veterinarian during their treatment. The information was then entered into the algorithm. The numeric output from the analytical algorithms provided a score of the individual sample from a dog with lymphoma from 0 to 5 at the time of blood draw, where 0 represents CR and 5 equates to active disease. The algorithm draws on the database of clinical information, including C-RP and Hapt values taken from dogs diagnosed to be have confirmed lymphoma (via cytology or histology) and dogs confirmed to be free of the disease for at least 6 months after the blood sample was taken. 24 The algorithm uses the input data by comparing it to the existing data base using kNN analysis to provide a likelihood score (0-5) of each new sample presented to the algorithm.
Statistical analysis
Receiver operating characteristic (ROC) analysis was performed in order to establish cLBT cut-off values corresponding to the WHO remission status ( Figure 1 and Table 4 ). Mann-Whitney U tests and Bland-Altman analysis ( Figure 2 ) were performed to determine the level of significance between remission status as determined by the veterinarians' assessment versus cLBT, using GraphPad Prism 6 software.
For the purposes of estimating Se and Sp confidence intervals, the paired cLBT and status observations were assumed to be independent; that some pairs were repeated observations from one patient was not considered to have a serious impact on these estimates.
Results
Setting cLBT cut-off values
Overall P (Mann-Whitney U) was less than 0.001 in the three different remission conditions (CR, PR and PD) (Figure 1 ). For CR the area under curve (AUC) was 0.94 [0.82-1.0 95% confidence interval (CI)], for PR AUC was 0.94 (0.82-1.0 95% CI) and for PD AUC was 0.97 (0.93-1.0 95% CI). The criterion for the best split was determined using ROC analysis to be the sum of sensitivity and specificity, which had to be higher than 1.80. For the PD group, the lowest cLBT value giving a sensitivity plus specificity sum of 1.80 (sensitivity 80.8% and specificity 100.0%) resulted in a cLBT cut-off value of ≥3.29. The ROC plot from the PR group of dogs revealed that the sum total was higher than 1.80 (sensitivity ranging from 81.3 to 93.8% and specificity 100% between those thresholds) between cLBT values of 1.93 and 3.29. Hence, the upper and lower cut-off cLBT values for the PR state were determined to be 3.29 and 1.93, respectively. Consequently, the CR group was defined as having cLBT values <1.93 (sensitivity 38.3% and specificity 100%). In summary, ROC analysis produced the following cLBT ranges for each of the three remission states studied: The week 0 samples were similarly analysed and a cLBT values of ≥3.29 was obtained for the pre-treatment active disease state. Note that the week 0 samples which were pre-treatment were not used in the determination of the post-treatment PD cLBT cut-off value, but the finding that ROC analysis produced identical thresholds for both sample groups was an encouraging observation.
Evaluation of overall test performance from all the samples submitted to the study, using the defined cLBT cut-off values obtained from ROC analysis, in comparison to the clinical status of each dog determined by clinical assessment and cytology at the time of sample collection showed 72 TP (true positive), 66 TN (true negative), 23 FP (false positive), 5 FN (false negative) and 30 borderline. Overall, sensitivity and specificity of the cLBT test compared to clinical assessment and cytology results was 93.5% (95% CI: 90.1-97.0%) and 74.2% (95% CI: 68.0-80.3), respectively. PPV and NPV were also calculated to be 75.8% (95% CI: 69.8-81.8%) and 93.0% (95% CI: 89.4-96.5%), respectively.
Bland-Altman analysis ( Figure 2 ) was applied to the two different methods of clinical assessment and cLBT. In order to provide a semi-quantitative means of comparing palpation data to the cLBT, it was necessary to convert the three different remission states as assessed by the referring veterinarian into numbers. For this reason the lymph node size information was implemented, which was in full agreement with the clinicians' diagnosis and the status of the disease for each case. Hence, the CR cases were converted to 0 (0% increase of the normal lymph node size), the PD group was converted to 1 (where lymph node size was at least double the normal size ≥100%) and PR to 0.5 (at least 50% lymph node reduction). 8 For the cLBT the actual output values ranging from 0 to 5 were used. The analysis showed that the 95% limits of agreement estimated by mean difference (2.33) were −1.44 to 6.11.
Comparison of cLBT values with clinicians' assessment of remission status
The median cLBT values were calculated for all the samples in each remission state as determined by the clinician. Twenty-nine pre-treatment "week 0" samples were submitted, plus a further 107 samples which were provided during the study and determined to be from patients in CR at that time, 16 in PR and 44 with PD. The PD group (post-treatment PD group) comprised all samples where a dog had enlarged lymph nodes which were confirmed to be positive for lymphoma by cytology. The pre-treatment "week 0" samples were also confirmed using cytology. Due to the absence of palpable lymph nodes, it was not possible to collect cytology data in the CR group. The median cLBT score in each of these four groups was shown to be ( Figure 3 ): "Week 0" 4.50 ± 0.18; CR 1.39 ± 0.14; PR 4.29 ± 0.27 and the PD group 4.29 ± 0.16.
The longitudinal patient responses to chemotherapy as determined using cLBT and the clinician's assessment by palpation were compared (Figure 4) . The percentage of patients that were not in CR according to the veterinarian's assessment (i.e., in the disease, PR or PD states) was compared with the mean cLBT score with 95% confidence intervals at each sampling time point (red and blue lines). These data show that the dogs appeared to take longer to enter remission when assessed using the cLBT than when assessed by palpation was used and that the dogs relapsed sooner according to the cLBT.
Further refinement of the cLBT cut-off values
Further analysis of the ROC data demonstrated an additional threshold range for the cLBT score between 0.83 and 1.93 which better reflected the dogs in CR (Table 5 and Figure 5 ). It was found that when the cLBT <0.83, the clinicians assessed 31 out of 34 (91.2%) as CR and when the cLBT value was in the range 0.83 ≥ cLBT <1.93 the clinicians assessed that 35 out of 37 (94.6%) were CR. In medium cLBT scores (≥1.93 to 3.29) the clinicians' diagnosis confirmed 18 CR out of a sample group of 23 (78.2%). In the high cLBT (≥3.29 to 4.11) and very high (≥4.11) cLBT scores the clinicians' diagnosis confirmed 22 PD out of 38 (57.9%) and 42 PD out of 64 total (65.6%), respectively.
Prognostic evaluation
Several aspects of the cLBT performance indicate a prognostic potential for the test. For 23 of the 57 dogs multiple blood samples were available during the period of clinical remission prior to relapse as determined by palpation. For these 23 animals the time of the pre-relapse samples varied from 1 to 49 weeks prior to relapse and therefore the samples were grouped by time before relapse and the average cLBT value for each group was calculated. It was found that longer than 8 weeks prior to relapse the cLBT value did not vary significantly during clinical remission and therefore the samples were split into five categories: 1-2, 3-4, 5-6, 7-8 and >8 weeks prior to relapse. The mean cLBT values were then calculated for the samples in each group and are shown in Figure 6 (the mean and standard error for each time group was: 1-2 weeks prior group 3.86 ± 0.35, 3-4 weeks prior group 3.72 ± 0.00, 5-6 weeks prior group 2.12 ± 1.07, 7-8 weeks prior group 2.06 ± 0.67 and more than 8 weeks prior group 1.16 ± 0.23). Samples taken fewer than 8 weeks prior to relapse showed a significant increase in cLBT values from those obtained 8 or more weeks before signs of lymphadenopathy indicated relapse.
(Mann-Whitney test, P = 0.0012).
The relationship between mean survival time and both the lowest cLBT value obtained during treatment, and the initial week 0 cLBT value, was examined. The mean survival time for dogs that went into CR (n = 47) as assessed by the veterinarians was 44.1 weeks whereas those that did not respond fully to chemotherapy (n = 9) survived for only 13.8 weeks (P = 0.02), including those dogs that went into PR. Similarly, a significant difference in mean survival time was also found when using cLBT to assess the remission status of each dog: 54.9 weeks mean survival time for dogs which achieved cLBT values <1.93 at any point during treatment (n = 44), compared to 17.4 weeks survival for those that never achieved that cLBT value (P = 0.003) during treatment (n = 13). Two groups of dogs that went into remission, defined as those which achieved a lowest cLBT value <0.83 (n = 28) and those which achieved a lowest value in the range 0.83 ≥ cLBT < 1.93 (n = 16), were further analysed. Dogs reaching a cLBT value <0.83 during treatment, survived 62.5 ± 11.4 weeks whereas those with the slightly higher minimum cLBT score during treatment survived for a shorter period of time of 41.9 ± 10.2 weeks. It was also observed that when the week 0 cLBT values were high (≥4.11) (n = 32) then the dog lived for a shorter time (with a median survival time of 5.5 weeks) than those with lower initial cLBT scores in the range 3.29 ≥ cLBT < 4.11 (n = 25) which had a median survival time of 14 weeks. The Kaplan-Meier graph for these two significantly different (P < 0.05) groups is shown in Figure 7 . Immunophenotyping showed that the group defined by week 0 cLBT values in the range 3.29 ≥ cLBT < 4.11 comprised 64.7% B-cell, 5.9% T-cell and 29.4% undetermined lymphoma cases and the group defined by a week 0 cLBT value ≥4.11 had a similar distribution with 50.0% B-cell, 8.3% T-cell and 41.7% non-differentiated lymphoma cases. In the survival analysis three patients were removed because they died due to other illnesses and not from lymphoma recurrence. The mean time to progression (TTP), i.e., from date of diagnosis/treatment to time to relapse was examined and compared with the lowest achieved cLBT values obtained during the initial chemotherapy treatment (Figure 8 ). For the group defined by the lowest achieved cLBT value (<0.83) the median TTP was 8.9 months, compared to 7.6 months for the group which achieved a lowest cLBT value in the range 0.83 ≥ cLBT < 1.93. Dogs which achieved a minimum cLBT score during treatment in the range 1.93 ≥ cLBT <3.29 had a median TTP of 4.8 months, those with a lowest value in the range 3.29 ≥ cLBT < 4.11 had a TTP of 2.3 months and those with a cLBT value which never went below 4.11 showed a TTP of 1.5 months. The trend of curves with the shortest TTP (3.29 ≥ cLBT < 4.11 and ≥4.11) was significantly different to the trend of longer TTP curves (<0.83 and 0.83 ≥ cLBT < 1.93) (P < 0.05).
Discussion
The calculated sensitivity, specificity, PPV, NPV and Bland-Altman analysis showed that the two different methods for monitoring the response to chemotherapy (the veterinarians' clinical assessment of remission status and the cLBT) in a canine population diagnosed with lymphoma were in good agreement. However, there was less agreement between the two methods of assessing disease status when the cLBT gave intermediate scores. Feedback from practicing veterinarians using palpation to determine remission status suggests most dogs achieve remission between three and four weeks into their chemotherapeutic scheme. However, the cLBT data obtained in this study showed that a low cLBT value (<1.93), indicating CR, was not achieved until after the seventh week of treatment (Figure 4 ). The effect of this is an apparent reduction in specificity of the cLBT when compared to palpation. However, whilst these dogs may have had the gross disease reduced by chemotherapy up to that point, the data indicate that dogs which achieved the lowest cLBT scores well below the CR cut-off had longer times to progression and longer survival times (Figures 7 and 8 ), indicating that remission status is monitored well, and perhaps better, by the cLBT and that some of the apparent false positive results obtained by cLBT are in fact true positives.
At the other end of the treatment regime another source of apparent false positive results arises from dogs appearing to come out of remission according to the cLBT assessment but showing no clinical signs of the disease. The data in Figure 6 indicate that the cLBT can detect relapse with a high degree of significance (P = 0.0012) up to 8 weeks before the appearance of physical signs. As the cLBT measures metabolic changes, whereas palpation determines only gross physical manifestation of the disease, it is likely that the observed discrepancies are due to the cLBT picking up recurrence in advance of enlarged lymph nodes being detectable. This could be a significant finding, enabling veterinarians to re-treat these dogs much earlier than is currently likely to happen. This is supported by Williams et al. 29 who identified a delay in relapse using lymph node palpation compared to their cytological assessments. There are currently no accurate prognostic indicators for canine lymphoma. Currently, clinical stage, WHO sub stage, grade and immunophenotype are used as a guideline. Although much research has been carried out with serum for levels of LDH or thymidine kinase 12, 21, 30 the prognostic significance has so far been unsubstantiated. The cLBT data presented here indicate a potential prognostic value both at the point of diagnosis from the initial cLBT value and during treatment from the lowest cLBT score achieved by chemotherapy. Dogs showing very high cLBT values (≥4.11) at the time of diagnosis lived for significantly shorter times than those dogs that had lower week 0 cLBT values (3.29 ≥ cLBT < 4.11) (Figure 7 ). This difference in survival time correlated with cLBT value could just be due to these two groupings actually identifying dogs with B-cell and T-cell lymphoma but the samples in these two groups that were immunophenotyped did not show a bias of either group towards B-cell or T-cell lymphoma.
In fact the relative proportions of T-and B-cell lymphomas in these two groups were similar (the group 3.29 ≥ cLBT < 4.11 (N = 25) comprised 64.7% B-cell, 5.9% T-cell and 29.4% undetermined lymphoma cases and the group cLBT ≥ 4.11 (N = 32) consisted of 50.0% B-cell, 8.3% T-cell and 41.7% non-differentiated lymphoma cases), which suggests that the differences in observed survival times were not due to immunophenotype of the disease. The different methodology used along the samples for the immunophenotyping is not believed to be a problem, because flow cytometry can only refine cytological findings. 31 It was also noted that the lower the cLBT value achieved during treatment, the greater the survival time was for those dogs. Dogs which achieved a minimum cLBT value of <1.93 lived approximately three times longer (54.9 weeks mean survival time) compared with those that did not achieve a cLBT value below this "complete remission" threshold set for the cLBT scoring. Furthermore there was a group of dogs which did achieve CR by cLBT and also achieved very low cLBT values <0.83 (n = 28) which survived 62.5 ± 11.4 weeks suggesting that the lowest cLBT value achieved during chemotherapy also has prognostic value. In the study, treatment was stopped at 25 or 28 weeks (according to the modified WisconsinMadison protocol), after which most of the dogs came out of remission according to both methods. On another note, there was no comparison attempted to test the efficacy of the two modified WM protocols used by the two practices. As this was a retrospective blinded study, there is currently no intervention data available to determine if greater treatment efficacy could have been achieved by treating more aggressively until a low cLBT score had been achieved for a determined amount of time. However, despite literature disclosing no positive evidence for treating for longer periods, 32, 33 these data (Figure 7) suggested that the lower the cLBT score achieved during treatment, the longer the overall time to progression for the dogs. The cLBT data suggested that remission takes longer to be achieved than indicated by palpation alone and relapse begins prior to the appearance of palpable lymph nodes. It is also considered that the earlier a client opts for more aggressive therapy, the more likely a dog will have a longer-lasting response. 11 The earlier detection potential of the cLBT could help with commencing re-induction or rescue therapy earlier than is currently likely to happen. Further study will be needed to determine if this approach could have a significant impact on survival rates. Finally, although palpation is a simple and convenient procedure, it is only really helpful when the disease affects peripheral lymph nodes and it is not possible to detect occult recurrence which therefore represents another potential clinical advantage of a serum-based biochemical test such as the cLBT as an alternative to diagnostic imaging and biopsy 31 .
Histologic grading during remission would have provided valuable further insight into the validity of the cLBT test. However, it is generally not practical to perform histology during the monitoring of remission and relapse of dogs undergoing treatment for lymphoma. Even without this additional insight the data presented here suggest that the cLBT, which uses a multivariate algorithm to combine multiple biochemical markers with other clinical symptoms to provide a relatively non-invasive, simple blood test which is cheap enough to perform repeatedly during treatment, has significant potential to assist in the monitoring of remission and recurrence of lymphoma in dogs being treated by chemotherapy.
